The company is actively investing in R&D, supply chain expansion, and physician education to drive the adoption of its GLP-1 receptor agonist drug candidates (such as Ozempic, Rybelsus, and Wegovy) across Europe
Eli Lilly has strong financial incentive to make the medication accessible, because broader adoption drives revenue far more effectively than keeping prices artificially high and limiting the patient pool
The $149 price is for the Starter tier, which is tirzepatide mixed with vitamin B6 rather than tirzepatide alone
Im hoping that could change in the next three to four years, maybe even sooner, for us to be able to compound those because I think there are a lot of benefits for patients using other peptides other than the weight loss peptides
Consumers who prioritize exact per-ingredient dosing transparency may wish to compare this label format with products that disclose individual ingredient quantities
The FDA approved the Wegovy pill in December 2025, the first once-daily oral GLP-1 approved for weight loss in adults, launching in the US in January 2026